Efficacy and safety of domestic dasatinib as second-line treatment for chronic myeloid leukemia patients in the chronic phase.
10.3760/cma.j.issn.0253-2727.2019.02.002
- Author:
Yi Lin CHEN
1
;
Long WANG
2
;
Guo Lin YAN
3
;
Zhuang Zhi YANG
4
;
Zhi Ping HUANG
5
;
You Shan ZHANG
6
;
Zhe ZHAO
7
;
Chu Cheng WAN
8
;
Ying BAO
9
;
Hang XIANG
10
;
Hua YIN
1
;
Li Feng CHEN
1
;
Ying Yuan XIONG
1
;
Li MENG
11
;
Wei Ming LI
1
Author Information
1. Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
2. The First People's Hospital of Jingmen, Jingmen 448000, China.
3. Xiangyang Central Hospital, Xiangyang 441021, China.
4. Suizhou Central Hospital, Suizhou 441300, China.
5. Jingzhou Central Hospital, Jingzhou 434020, China.
6. The First People's Hospital of Jingzhou, Jingzhou 434000, China.
7. Min Da Hospital Affiliated to Hubei Institute for Nationalities, Enshi 445000, China.
8. Shiyan Taihe Hospital, Shiyan 442000, China.
9. The First People's Hospital of Xiangyang, Xiangyang 441000, China.
10. Central Hospital of Enshi Autonomous Prefecture, Enshi 445000, China.
11. Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
- Publication Type:Journal Article
- Keywords:
Domestic dasatinib;
Efficiency;
Leukemia, myeloid, chronic;
Safety
- MeSH:
Antineoplastic Agents;
Dasatinib/therapeutic use*;
Humans;
Imatinib Mesylate;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy*;
Protein Kinase Inhibitors;
Retrospective Studies;
Treatment Outcome
- From:
Chinese Journal of Hematology
2019;40(2):98-104
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To investigate the efficiency and safety of domestic tyrosine kinase inhibitor (TKI) dasatinib (Yinishu) as second-line treatment for patients with chronic myeloid leukemia in chronic phase (CML-CP). Methods: A retrospective analysis of clinical data of CML-CP patients who received domestic dasatinib as second-line treatment in the CML collaborative group hospitals of Hubei province from March 2016 to July 2018 was performed. The optimal response rate, the cumulative complete cytogenetic response (CCyR), the cumulative major molecular responses (MMR), progression free survival (PFS), event free survival (EFS) and adverse effects (AEs) of the patients were assessed at 3, 6 and 12 months of treatment. Results: A total of 83 CML-CP patients were enrolled in this study. The median follow-up time was 23 months. The optimal response rates at 3, 6 and 12 months in 83 CML-CP patients treated with dasatinib were 77.5% (54/71), 72.6% (61/75) and 60.7% (51/69), respectively. By the end of follow-up, the cumulative CCyR and MMR rates were 65.5% (55/80) and 57.1% (48/73), respectively. The median time to achieving CCyR and MMR was 3 months. During follow-up time, the PFS rate was 94.0% (79/83) and the EFS rate was 77.4% (65/83). The most common non-hematological AEs of dasatinib were edema (32.5%), rash itching (18.1%) and fatigue (13.3%). The common hematological AEs of dasatinib were thrombocytopenia (31.3%), leukopenia (19.3%) and anemia (6.0%). Conclusion: Domestic dasatinib was effective and safe as the second-line treatment of CML-CP patients and it can be used as an option for CML-CP patients.
